CervoMed Inc. (CRVO)

Market Cap	48.39M
Revenue (ttm)	9.31M
Net Income (ttm)	-18.67M
Shares Out	8.70M
EPS (ttm)	-2.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	222,393
Open	6.06
Previous Close	5.93
Day's Range	5.56 - 6.15
52-Week Range	1.80 - 20.63
Beta	n/a
Analysts	Strong Buy
Price Target	25.57 (+359.89%)
Earnings Date	Aug 8, 2025

About CRVO

CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. It is being evaluated in a Phase 2b ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 15
• Stock Exchange: NASDAQ
• Ticker Symbol: CRVO
• Website: https://www.cervomed.com

Financial Performance

In 2024, CervoMed's revenue was $9.74 million, an increase of 36.29% compared to the previous year's $7.14 million. Losses were -$16.29 million, 650.1% more than in 2023.

Analyst Summary

According to 8 analysts, the average rating for CRVO stock is "Strong Buy." The 12-month stock price target is $25.57, which is an increase of 359.89% from the latest price.

Price Target

$25.57

(359.89% upside)

Analyst Consensus: Strong Buy